Medikamentöse Therapie des fortgeschrittenen Blasenkarzinoms: Neue Entwicklungen 2014

Translated title of the contribution: Pharmaceutical treatment of advanced urinary bladder cancer: New developments in 2014

S. C. Schmid, J. E. Gschwend, M. Retz

Research output: Contribution to journalArticlepeer-review

Abstract

The perioperative treatment of muscle-invasive bladder cancer has become a standard procedure in recent years. New agents, such as programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors have opened up the door for immunomodulation therapy of metastasized bladder cancer. This article focuses on data which have changed or have the potential to change the pharmaceutical treatment of advanced bladder cancer with a review of the literature in Medline PubMed and proceedings of major meetings, e.g. the European Association of Urology (EAU), the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium (ASCO GU) and the American Urological Association (AUA).

Translated title of the contributionPharmaceutical treatment of advanced urinary bladder cancer: New developments in 2014
Original languageGerman
Pages (from-to)1535-1542
Number of pages8
JournalUrologe - Ausgabe A
Volume53
Issue number10
DOIs
StatePublished - 8 Oct 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pharmaceutical treatment of advanced urinary bladder cancer: New developments in 2014'. Together they form a unique fingerprint.

Cite this